Abstract
Cardio-oncology is an emerging subspecialty dedicated to personalized patient risk assessment, prevention, detection, and treatment of potential cardiovascular effects from cancer therapy. The reason for this evolving need for specialized cardiac care in cancer patients is because of the acute and chronic cardiovascular complications of cancer therapy, emerging data that early detection of cardiotoxicity improves patient outcomes, and finally that cardiovascular interventions have to be balanced with cancer therapeutics to provide the patient with the best possible oncologic and cardiovascular outcomes.
| Original language | English |
|---|---|
| Title of host publication | Oncology |
| Publisher | wiley |
| Pages | 486-500 |
| Number of pages | 15 |
| ISBN (Electronic) | 9781119189596 |
| ISBN (Print) | 9781119189558 |
| DOIs | |
| State | Published - 30 Aug 2019 |
Keywords
- Anthracyclines
- Cardio-oncology
- Cardioprotection
- Cardiotoxicity
- Cardiotoxicity risk score (CRS)
- Dexrazoxane
- Doxorubicin
- Global longitudinal score
- Trastuzumab